Table 2.

Hormone therapy use in women and risk of Parkinson disease; ever use

	Case	Control	OR (95% CI) Crude	OR (95% CI) Adjusteda
no HT use	84	151	1.0 (Ref)	1.0 (Ref)
Conjugated estrogen use only	17	42	0.7 (0.4–1.4)	0.6 (0.3–1.3)
Esterified estrogen use only	16	7	4.1 (1.6–10.4)	3.1 (1.0–9.8)
Combination	20	27	1.3 (0.7–2.5)	1.0 (0.4–2.7)
no HT use	84	151	1.0 (Ref)	1.0 (Ref)
Conjugated estrogen use only
With progestin	7	8	1.6 (0.6–4.5)	1.7 (0.6–5.0)
Without progestin	7	26	0.5 (0.2–1.2)	0.5 (0.2–1.2)
Esterified estrogen use only
With progestin	12	4	5.4 (1.7–17.2)	6.9 (2.1–22.9)
Without progestin	4	2	3.6 (0.7–20.0)	3.0 (0.5–16.9)
Combination*	23	36	1.1 (0.6–2.1)	1.4 (0.7–2.6)

^aadjusted for duration of enrollment at GHC, and smoking (>100 cigarettes in lifetime); plus progestin use (ever) in the top model

^*Note: 3 cases and 8 controls had prescriptions for both conjugated estrogens with and without progestin, and 1 control had prescriptions for esterified estrogen with and without progestin